"""
Question: 1101 

Evidence: This retrospective cohort study enrolled individuals residing in southern Taiwan, who were infected with HIV-1 and failed treatment with an NNRTI-based STR from 2015 to 2020. A total of 107 patients were included. Our findings showed a high rate of doravirine cross-resistance in patients with NNRTI-based STR treatment failure.

Rationale: The study prospectively assembled and analyzed a cohort of 107 patients from 2015–2020 with new analyses of their resistance profiles, indicating it reports original, previously unpublished clinical sequencing and resistance data.

Answer: Yes
"""

"""
Question: 1102 

Evidence: ViroSeq HIV-1 Genotyping System version v2.8 was used to test resistance for PR/RT (pol gene), and in-house sequencing was used to test resistance to integrase strand transfer inhibitors (INSTIs) (pol gene). Sanger sequencing successfully identified the PR/RT (n=107) and INSTI (n=12) regions in all cases.

Rationale: The methods explicitly describe sequencing of HIV-1 PR/RT and integrase regions and confirm successful identification, indicating HIV sequences were reported.

Answer: Yes
"""

"""
Question: 1103 

Evidence: This retrospective cohort study enrolled individuals residing in southern Taiwan, who were infected with HIV-1 and failed treatment with an NNRTI-based STR from 2015 to 2020. ViroSeq HIV-1 Genotyping System version v2.8 was used to test resistance for PR/RT (pol gene), and in-house sequencing was used to test resistance to integrase strand transfer inhibitors (INSTIs) (pol gene).

Rationale: The paper describes clinical genotypic resistance testing in patient samples and does not mention any laboratory in vitro passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: Mutations associated with drug resistance were identified using the 2019 International Antiviral Society-USA list of drug-resistant mutations in HIV, and drug susceptibility was assessed according to the Stanford HIV Drug Resistance Database version 9. ViroSeq HIV-1 Genotyping System version v2.8 was used to test resistance for PR/RT (pol gene), and in-house sequencing was used to test resistance to integrase strand transfer inhibitors (INSTIs) (pol gene).

Rationale: The study used genotypic interpretation (Stanford HIVdb) rather than performing novel in vitro phenotypic susceptibility assays.

Answer: No
"""

"""
Question: 2101 

Evidence: ViroSeq HIV-1 Genotyping System version v2.8 was used to test resistance for PR/RT (pol gene), and in-house sequencing was used to test resistance to integrase strand transfer inhibitors (INSTIs) (pol gene). Sanger sequencing successfully identified the PR/RT (n=107) and INSTI (n=12) regions in all cases.

Rationale: Although sequencing was performed, the paper does not provide any GenBank accession numbers for these sequences.

Answer: No
"""

"""
Question: 2102 

Evidence: ViroSeq HIV-1 Genotyping System version v2.8 was used to test resistance for PR/RT (pol gene), and in-house sequencing was used to test resistance to integrase strand transfer inhibitors (INSTIs) (pol gene). Sanger sequencing successfully identified the PR/RT (n=107) and INSTI (n=12) regions in all cases.

Rationale: No GenBank accession numbers are reported for any clinical isolates; therefore, accession numbers for non-laboratory isolates are also not provided.

Answer: No
"""

"""
Question: 2103 

Evidence: ViroSeq HIV-1 Genotyping System version v2.8 was used to test resistance for PR/RT (pol gene), and in-house sequencing was used to test resistance to integrase strand transfer inhibitors (INSTIs) (pol gene). Sanger sequencing successfully identified the PR/RT (n=107) and INSTI (n=12) regions in all cases.

Rationale: The article does not list any GenBank accession numbers.

Answer: NA
"""

"""
Question: 2202 

Evidence: The most common NRTI resistance-associated mutations were M184V (57.9%) and K65R (20.6%); for NNRTIs K103N (35.5%), V179D (20.6%) and L100I (15%). The prevalence of mutations associated with drug resistance to INSTIs, PIs, NNRTIs and NRTIs among the 107 enrolled patients is shown in Figure 2.

Rationale: The paper provides aggregate frequencies of mutations rather than per-sample lists of mutations for individual isolates.

Answer: No
"""

"""
Question: 2301 

Evidence: Taiwanese patients infected with HIV-1 who failed NNRTI-based STR treatment were enrolled. Of the 107 enrolled patients, ... Overall, 89% of the patients had subtype B HIV-1 strains.

Rationale: The study focuses on HIV-1-infected individuals.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: Overall, 89% of the patients had subtype B HIV-1 strains and 7% had subtype CRF01_AE (Table 1). Table 1 shows additional subtypes including C (0.9%), CRF07_BC (2.8%) and A (0.9%).

Rationale: The text reports the distribution of HIV-1 subtypes among sequenced patients.

Answer: Subtype B (about 89%), CRF01_AE (about 7%), with smaller numbers of C, CRF07_BC, and A.
"""

"""
Question: 2303 

Evidence: ViroSeq HIV-1 Genotyping System version v2.8 was used to test resistance for PR/RT (pol gene), and in-house sequencing was used to test resistance to integrase strand transfer inhibitors (INSTIs) (pol gene). Sanger sequencing successfully identified the PR/RT (n=107) and INSTI (n=12) regions in all cases.

Rationale: The paper sequenced the pol gene regions including protease/reverse transcriptase (PR/RT) and integrase.

Answer: pol gene (PR/RT) and integrase
"""

"""
Question: 2304 

Evidence: ViroSeq HIV-1 Genotyping System version v2.8 was used to test resistance for PR/RT (pol gene), and in-house sequencing was used to test resistance to integrase strand transfer inhibitors (INSTIs) (pol gene). Sanger sequencing successfully identified the PR/RT (n=107) and INSTI (n=12) regions in all cases.

Rationale: The study reports sequencing results from the HIV-1 pol gene.

Answer: Yes
"""

"""
Question: 2401 

Evidence: This retrospective cohort study enrolled individuals residing in southern Taiwan. The Institutional Review Board of Kaohsiung Veterans General Hospital, Taiwan, approved this study.

Rationale: The sequences come from individuals in Taiwan (specifically southern Taiwan).

Answer: Taiwan (southern Taiwan)
"""

"""
Question: 2402 

Evidence: This retrospective cohort study enrolled individuals ... from 2015 to 2020.

Rationale: The enrollment period indicates the years the samples were obtained.

Answer: 2015 to 2020
"""

"""
Question: 2502 

Evidence: Sanger sequencing successfully identified the PR/RT (n=107) and INSTI (n=12) regions in all cases.

Rationale: The methods explicitly state the use of Sanger sequencing.

Answer: Yes
"""

"""
Question: 2503 

Evidence: Sanger sequencing successfully identified the PR/RT (n=107) and INSTI (n=12) regions in all cases. ViroSeq HIV-1 Genotyping System version v2.8 was used to test resistance for PR/RT.

Rationale: Only Sanger (population) sequencing is described; no next-generation sequencing is mentioned.

Answer: No
"""

"""
Question: 2504 

Evidence: ViroSeq HIV-1 Genotyping System version v2.8 was used to test resistance for PR/RT (pol gene), and in-house sequencing was used to test resistance to INSTIs (pol gene). Sanger sequencing successfully identified the PR/RT (n=107) and INSTI (n=12) regions in all cases.

Rationale: The paper does not state that samples were cloned prior to sequencing; it describes standard population sequencing workflows.

Answer: NA
"""

"""
Question: 2505 

Evidence: ViroSeq HIV-1 Genotyping System version v2.8 was used to test resistance for PR/RT (pol gene), and in-house sequencing was used to test resistance to INSTIs (pol gene). Sanger sequencing successfully identified the PR/RT (n=107) and INSTI (n=12) regions in all cases.

Rationale: There is no mention of single-genome sequencing.

Answer: NA
"""

"""
Question: 2506 

Evidence: ViroSeq HIV-1 Genotyping System version v2.8 was used to test resistance for PR/RT (pol gene), and in-house sequencing was used to test resistance to INSTIs (pol gene).

Rationale: The study does not mention molecular cloning.

Answer: NA
"""

"""
Question: 2601 

Evidence: ViroSeq HIV-1 Genotyping System version v2.8 was used to test resistance for PR/RT (pol gene), and in-house sequencing was used to test resistance to integrase strand transfer inhibitors (INSTIs) (pol gene).

Rationale: The paper does not explicitly state that sequencing was performed on plasma; therefore, this cannot be determined from the text.

Answer: NA
"""

"""
Question: 2602 

Evidence: ViroSeq HIV-1 Genotyping System version v2.8 was used to test resistance for PR/RT (pol gene), and in-house sequencing was used to test resistance to integrase strand transfer inhibitors (INSTIs) (pol gene).

Rationale: The paper does not mention PBMC-based sequencing.

Answer: NA
"""

"""
Question: 2603 

Evidence: 

Rationale: The paper does not specify the number of plasma virus sequences.

Answer: NA
"""

"""
Question: 2604 

Evidence: 

Rationale: The paper does not specify the number of PBMC virus sequences.

Answer: NA
"""

"""
Question: 2605 

Evidence: The definition of virological failure was an HIV-1 viral load of ≥1000 copies/mL. The inclusion criteria included those patients with virological failure to NNRTI-based STRs and underwent an HIV genotypic drug resistance testing at our hospital.

Rationale: Sequencing was conducted in individuals meeting virological failure criteria (≥1000 copies/mL), indicating active viral replication at the time of sampling.

Answer: Yes
"""

"""
Question: 2606 

Evidence: ViroSeq HIV-1 Genotyping System version v2.8 was used to test resistance for PR/RT (pol gene), and in-house sequencing was used to test resistance to integrase strand transfer inhibitors (INSTIs) (pol gene).

Rationale: The source (plasma RNA vs. proviral DNA) is not specified; there is no explicit mention of sequencing from proviral DNA reservoirs.

Answer: NA
"""

"""
Question: 2701 

Evidence: The median age (interquartile range, IQR) of the 107 patients was 33 (28–40) years. 

Rationale: The cohort consisted of adults, not infants or children.

Answer: No
"""

"""
Question: 2702 

Evidence: This retrospective cohort study enrolled individuals residing in southern Taiwan. 

Rationale: The study is observational and not described as a clinical trial.

Answer: No
"""

"""
Question: 2703 

Evidence: This retrospective cohort study enrolled individuals residing in southern Taiwan. 

Rationale: Because it is not a clinical trial, none of the individuals were all in a clinical trial.

Answer: No
"""

"""
Question: 3101 

Evidence: A total of 107 patients were included. Sanger sequencing successfully identified the PR/RT (n=107) and INSTI (n=12) regions in all cases.

Rationale: The cohort comprised 107 individuals, all of whom had genotypic sequencing results for at least PR/RT.

Answer: 107
"""

"""
Question: 3102 

Evidence: The inclusion criteria included those patients with virological failure to NNRTI-based STRs and underwent an HIV genotypic drug resistance testing at our hospital. Sanger sequencing successfully identified the PR/RT (n=107) and INSTI (n=12) regions in all cases.

Rationale: All enrolled individuals underwent HIV genotypic sequencing as part of the study.

Answer: Yes
"""

"""
Question: 4101 

Evidence: Among the 107 patients, only 8 underwent pretreatment genotypic resistance testing, and they all had the wild type.

Rationale: Pretreatment genotypic testing implies ART-naive sampling for those 8 individuals.

Answer: Yes
"""

"""
Question: 4102 

Evidence: This retrospective cohort study enrolled individuals ... who were infected with HIV-1 and failed treatment with an NNRTI-based STR from 2015 to 2020. Sanger sequencing successfully identified the PR/RT (n=107) and INSTI (n=12) regions in all cases.

Rationale: The main cohort consists of ART-experienced individuals with NNRTI-based STR failure whose viruses were sequenced.

Answer: Yes
"""

"""
Question: 4103 

Evidence: Among the 107 patients, only 8 underwent pretreatment genotypic resistance testing, and they all had the wild type. This retrospective cohort study enrolled individuals ... who failed treatment with an NNRTI-based STR.

Rationale: The study includes sequences from both ART-naive (pretreatment) and ART-experienced (treatment-failure) individuals.

Answer: Yes
"""

"""
Question: 4104 

Evidence: Among the 107 patients, only 8 underwent pretreatment genotypic resistance testing, and they all had the wild type.

Rationale: The number of ART-naive samples sequenced is explicitly given as eight.

Answer: 8
"""

"""
Question: 4105 

Evidence: The initial regimen when HIV was diagnosed was STR in 39 (36.4%) patients, NNRTI-based multiple-tablet regimen (MTR) in 54 (50.5%) patients, PI-based MTR in 12 (11.2%) patients and INSTI-based MTR in two (1.9%) patients. The median (IQR) frequency of switching regimen before switching to the current STR was 1 (0–2). The last regimen before switching to the current STR (n=78) was STR in 17 (21.8%) patients, NNRTI-based MTR in 47 (60.3%) patients, PI-based MTR in 11 (14.1%) patients and INSTI-based MTR in 3 (3.8%) patients.

Rationale: The paper provides detailed ART histories including initial regimen, regimen switches, and last regimen before the failed STR.

Answer: Yes
"""

"""
Question: 4201 

Evidence: Among the 107 patients, only 8 underwent pretreatment genotypic resistance testing, and they all had the wild type.

Rationale: Reporting pretreatment resistance results (all wild type) provides information on transmitted drug resistance prevalence in this cohort subset.

Answer: Yes
"""

"""
Question: 4202 

Evidence: Among the 107 patients, only 8 underwent pretreatment genotypic resistance testing, and they all had the wild type.

Rationale: This directly reports pretreatment resistance prevalence information (0% in 8 individuals).

Answer: Yes
"""

"""
Question: 4301 

Evidence: The initial regimen when HIV was diagnosed was STR in 39 (36.4%) patients, NNRTI-based MTR in 54 (50.5%) patients, PI-based MTR in 12 (11.2%) patients and INSTI-based MTR in two (1.9%) patients. The prevalence rates of resistance to nucleoside reverse transcriptase inhibitors (NRTIs), NNRTIs, protease inhibitors (PIs) and integrase strand transfer inhibitors (INSTIs) were 76%, 86%, 3% and 2%, respectively.

Rationale: The study population received regimens containing NRTIs, NNRTIs, PIs, and INSTIs.

Answer: NRTIs, NNRTIs, PIs, INSTIs
"""

"""
Question: 4302 

Evidence: INSTI-based MTR in two (1.9%) patients. Five of the 12 patients who underwent INSTI resistance testing had previous exposure to INSTIs.

Rationale: The paper reports individuals who received integrase inhibitors.

Answer: Yes
"""

"""
Question: 4303 

Evidence: PI-based MTR in 12 (11.2%) patients. The last regimen before switching to the current STR (n=78) included PI-based MTR in 11 (14.1%) patients.

Rationale: The study includes individuals who received protease inhibitors.

Answer: Yes
"""

"""
Question: 4304 

Evidence: The initial regimen when HIV was diagnosed was STR in 39 (36.4%) patients, NNRTI-based MTR in 54 (50.5%) patients, PI-based MTR in 12 (11.2%) patients and INSTI-based MTR in two (1.9%) patients. The last regimen before switching to the current STR (n=78) was STR in 17 (21.8%) patients, NNRTI-based MTR in 47 (60.3%) patients, PI-based MTR in 11 (14.1%) patients and INSTI-based MTR in 3 (3.8%) patients.

Rationale: Multiple differing regimens were used, indicating not all individuals received the same ART.

Answer: No
"""

"""
Question: 4305 

Evidence: Five of the 12 patients who underwent INSTI resistance testing had previous exposure to INSTIs. INSTI-based MTR in two (1.9%) patients.

Rationale: Some individuals had prior INSTI exposure; therefore, not all were INSTI-naive.

Answer: No
"""

"""
Question: 4403 

Evidence: Frequency of regimen switching: 0 (n=29), 1 (n=43), 2 (n=22), 3 (n=9), 4 (n=3), 7 (n=1).

Rationale: Individuals with more than one regimen are those with ≥1 switch: 43+22+9+3+1 = 78.

Answer: 78
"""

"""
Question: 4404 

Evidence: Frequency of regimen switching: 0 (n=29), 1 (n=43), 2 (n=22), 3 (n=9), 4 (n=3), 7 (n=1).

Rationale: More than two regimens corresponds to ≥2 switches: 22+9+3+1 = 35.

Answer: 35
"""

"""
Question: 4405 

Evidence: Frequency of regimen switching: 0 (n=29), 1 (n=43), 2 (n=22), 3 (n=9), 4 (n=3), 7 (n=1).

Rationale: The distribution shows varying numbers of regimens across individuals.

Answer: No
"""

"""
Question: 4406 

Evidence: Frequency of regimen switching: 0 (n=29), 1 (n=43), 2 (n=22), 3 (n=9), 4 (n=3), 7 (n=1).

Rationale: Many individuals had one or more switches; therefore, not all received only one regimen.

Answer: No
"""

"""
Question: 4501 

Evidence: INSTI in IR (n=6): DTG 3 (50.0). Last INSTIs before switching to the failed STRs (n=9): DTG 6 (66.7).

Rationale: The paper reports counts of dolutegravir use within subset categories (initial regimen and last INSTI before switching), but it does not provide a deduplicated total number across the whole cohort.

Answer: NA
"""

"""
Question: 4502 

Evidence: PI-based MTR in 12 (11.2%) patients. Boosted-PI is reported, but specific PI agents are not enumerated in the cohort description.

Rationale: The paper does not specify how many individuals received darunavir.

Answer: NA
"""

"""
Question: 5101 

Evidence: Overall, 88% of the patients had drug resistance to any of the four classes of antiretroviral drugs. pol resistance Yes 94 (87.9).

Rationale: 88% of 107 corresponds to 94 individuals with one or more resistance mutations.

Answer: 94
"""

"""
Question: 5102 

Evidence: The prevalence rates of ... INSTI drug resistance were 2%. The most common INSTI resistance-associated mutations were G148H (0.9%) and G140S (0.9%).

Rationale: Two distinct INSTI mutations at 0.9% each imply two individuals.

Answer: 2
"""

"""
Question: 5103 

Evidence: Overall, 28% of the 107 patients had resistance to tenofovir (TDF).

Rationale: 28% of 107 is approximately 30 individuals.

Answer: 30
"""

"""
Question: 5104 

Evidence: The most common INSTI resistance-associated mutations were G148H (0.9%) and G140S (0.9%).

Rationale: These are the specific INSTI mutations reported.

Answer: G148H, G140S
"""

"""
Question: 6101 

Evidence: Mutations associated with drug resistance were identified using the 2019 International Antiviral Society-USA list of drug-resistant mutations in HIV, and drug susceptibility was assessed according to the Stanford HIV Drug Resistance Database version 9. 

Rationale: No phenotypic susceptibility testing method was performed or described; resistance was inferred genotypically.

Answer: NA
"""

"""
Question: 6102 

Evidence: drug susceptibility was assessed according to the Stanford HIV Drug Resistance Database version 9. 

Rationale: No IC50/IC90 values are reported; resistance is predicted from genotype.

Answer: No
"""

"""
Question: 6103 

Evidence: drug susceptibility was assessed according to the Stanford HIV Drug Resistance Database version 9.

Rationale: The paper does not report any phenotypic IC50 fold change values.

Answer: No
"""

"""
Question: 6104 

Evidence: Mutations associated with drug resistance were identified ... and drug susceptibility was assessed according to the Stanford HIV Drug Resistance Database version 9.

Rationale: No phenotypic assay is described.

Answer: NA
"""

"""
Question: 6105 

Evidence: 

Rationale: The paper does not include replication capacity measurements.

Answer: No
"""

"""
Question: 6106 

Evidence: 

Rationale: No phenotypic susceptibility testing was performed; hence, no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: This retrospective cohort study enrolled individuals ... and underwent an HIV genotypic drug resistance testing. ViroSeq HIV-1 Genotyping System version v2.8 was used to test resistance for PR/RT, and in-house sequencing was used to test resistance to INSTIs.

Rationale: The study analyzed clinical samples without creating site-directed mutants.

Answer: No
"""

"""
Question: 7102 

Evidence: This retrospective cohort study enrolled individuals ... who failed treatment with an NNRTI-based STR. 

Rationale: The study did not perform in vitro passage experiments; it analyzed patient-derived sequences.

Answer: No
"""